{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T02:31:48Z","timestamp":1761964308580},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2011,4,19]],"date-time":"2011-04-19T00:00:00Z","timestamp":1303171200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1007\/s11926-011-0171-0","type":"journal-article","created":{"date-parts":[[2011,4,18]],"date-time":"2011-04-18T08:57:44Z","timestamp":1303117064000},"page":"192-198","source":"Crossref","is-referenced-by-count":22,"title":["Mechanisms of Action of Intravenous Immunoglobulin in Inflammatory Muscle Disease"],"prefix":"10.1007","volume":"13","author":[{"given":"Adam","family":"Quick","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rup","family":"Tandan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,4,19]]},"reference":[{"key":"171_CR1","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S0140-6736(81)92400-4","volume":"1","author":"P Imbach","year":"1981","unstructured":"Imbach P, Barandun S, d\u2019Apuzzo V, et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet. 1981;1:1228\u201331.","journal-title":"Lancet"},{"key":"171_CR2","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1182\/blood.V62.2.480.480","volume":"62","author":"JB Bussel","year":"1983","unstructured":"Bussel JB, Kimberly RP, Inman RD, et al. Intravenous gammaglobulin treatment of chronic idiopathic thrombocytopenic purpura. Blood. 1983;62:480\u20136.","journal-title":"Blood"},{"key":"171_CR3","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1159\/000115560","volume":"22","author":"E Schuller","year":"1983","unstructured":"Schuller E, Govaerts A. First results of immunotherapy with immunoglobulin G in multiple sclerosis patients. Eur Neurol. 1983;22:205\u201312.","journal-title":"Eur Neurol"},{"key":"171_CR4","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S0140-6736(84)90469-0","volume":"1","author":"P Gajdos","year":"1984","unstructured":"Gajdos P, Outin H, Elkharrat D, et al. High-dose intravenous gammaglobulin for myasthenia gravis. Lancet. 1984;1:406\u20137.","journal-title":"Lancet"},{"key":"171_CR5","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/mus.21433","volume":"40","author":"PD Donofrio","year":"2009","unstructured":"\u2022\u2022 Donofrio PD, Berger A, Brannagan 3rd TH, et al. Consensus statement: the use of intravenous immunoglobulin in the treatment of neuromuscular conditions report of the AANEM Ad Hoc Committee. Muscle Nerve. 2009;40:890\u2013900. This report from the American Academy of Neuromuscular and Electrodiagnostic Medicine Task Force provides a comprehensive, evidence-based consensus statement on the treatment of immune-mediated neuromuscular disorders with IVIG.","journal-title":"Muscle Nerve"},{"key":"171_CR6","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/j.jaci.2009.09.046","volume":"125","author":"HW Schroeder Jr","year":"2010","unstructured":"Schroeder Jr HW, Cavacini L. Structure and function of Immunoglobulins. J Allergy Clin Immunol. 2010;125:S41\u201352.","journal-title":"J Allergy Clin Immunol"},{"key":"171_CR7","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1056\/NEJMra993360","volume":"345","author":"MD Kazatchkine","year":"2001","unstructured":"Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med. 2001;345:747\u201355.","journal-title":"N Engl J Med"},{"key":"171_CR8","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0161-5890(88)90088-0","volume":"25","author":"DL Tankersley","year":"1988","unstructured":"Tankersley DL, Preston MS, Finlayson JS. Immunoglobulin G dimer: an idiotype-anti-idiotype complex. Mol Immunol. 1988;25:41\u20138.","journal-title":"Mol Immunol"},{"key":"171_CR9","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1182\/blood-2007-03-077057","volume":"110","author":"T Tha-In","year":"2007","unstructured":"Tha-In T, Metselaar HJ, Tilanus HW, et al. Intravenous immunoglobulins suppress T-cell priming by modulating the bidirectional interaction between dendritic cells and natural killer cells. Blood. 2007;110:3253\u201362.","journal-title":"Blood"},{"key":"171_CR10","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1182\/blood-2002-05-1447","volume":"101","author":"J Bayry","year":"2003","unstructured":"Bayry J, Lacroix-Desmazes S, Carbonneil C, et al. Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood. 2003;101:758\u201365.","journal-title":"Blood"},{"key":"171_CR11","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/BF00918680","volume":"11","author":"R Liblau","year":"1991","unstructured":"Liblau R, Gajdos P, Bustarret FA, et al. Intravenous gamma-globulin in myasthenia gravis: interaction with anti-acetylcholine receptor autoantibodies. J Clin Immunol. 1991;11:128\u201331.","journal-title":"J Clin Immunol"},{"issue":"3","key":"171_CR12","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1365-2249.1993.tb03407.x","volume":"92","author":"T Vassilev","year":"1993","unstructured":"Vassilev T, Gelin C, Kaveri SV, et al. Antibodies to the CD5 molecule in normal human immunoglobulins for therapeutic use (intravenous immunoglobulins, IVIg). Clin Exp Immunol. 1993;92(3):369\u201372.","journal-title":"Clin Exp Immunol"},{"key":"171_CR13","doi-asserted-by":"crossref","first-page":"11409","DOI":"10.1016\/S0021-9258(19)78139-3","volume":"269","author":"ML Diegel","year":"1994","unstructured":"Diegel ML, Rankin BM, Bolen JB, et al. Cross-linking of Fc gamma receptor to surface immunoglobulin on B cells provides an inhibitory signal that closes the plasma membrane calcium channel. J Biol Chem. 1994;269:11409\u201316.","journal-title":"J Biol Chem"},{"key":"171_CR14","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.4049\/jimmunol.161.7.3781","volume":"161","author":"E Bonnin","year":"1998","unstructured":"Bonnin E, Kazatchkine MD, Ruberti G, et al. Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway. J Immunol. 1998;161:3781\u201390.","journal-title":"J Immunol"},{"key":"171_CR15","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1172\/JCI117520","volume":"94","author":"M Basta","year":"1994","unstructured":"Basta M, Dalakas MC. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest. 1994;94:1729\u201335.","journal-title":"J Clin Invest"},{"key":"171_CR16","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.intimp.2005.11.013","volume":"6","author":"J Bayary","year":"2006","unstructured":"Bayary J, Dasgupta S, Misra N, et al. Intravenous immunoglobulin in autoimmune disorders: an insight into the immunoregulatory mechanisms. Int Immunopharmacol. 2006;6:528\u201334.","journal-title":"Int Immunopharmacol"},{"key":"171_CR17","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","volume":"329","author":"MC Dalakas","year":"1993","unstructured":"Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med. 1993;329:1993\u20132000.","journal-title":"N Engl J Med"},{"key":"171_CR18","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1159\/000093870","volume":"55","author":"S Hurnaus","year":"2006","unstructured":"Hurnaus S, Mueller-Felber W, Pongratz D, et al. Serum levels of matrix metalloproteinases-2 and -9 and their tissue inhibitors in inflammatory neuromuscular disorders. Eur Neurol. 2006;55:204\u20138.","journal-title":"Eur Neurol"},{"key":"171_CR19","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/mus.10529","volume":"29","author":"E Carmeli","year":"2004","unstructured":"Carmeli E, Moas M, Reznick AZ, Coleman R. Matrix metalloproteinases and skeletalmuscle: a brief review. Muscle Nerve. 2004;29:191\u20137.","journal-title":"Muscle Nerve"},{"key":"171_CR20","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1067\/mai.2001.117822","volume":"108","author":"VL Ott","year":"2001","unstructured":"Ott VL, Fong DC, Cambier JC, et al. Fc gamma RIIB as a potential molecular target for intravenous gamma globulin therapy. J Allergy Clin Immunol. 2001;108:S95\u20138.","journal-title":"J Allergy Clin Immunol"},{"key":"171_CR21","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1126\/science.291.5503.484","volume":"291","author":"A Samuelsson","year":"2001","unstructured":"Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science. 2001;291:484\u20136.","journal-title":"Science"},{"issue":"Suppl 1","key":"171_CR22","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1365-2249.2009.04022.x","volume":"58","author":"A Durandy","year":"2009","unstructured":"\u2022 Durandy A, Kaveri SV, Kuijpers TW, et al. Intravenous immunoglobulins\u2014understanding properties and mechanisms. Clin Exp Immunol. 2009;58 Suppl 1:2\u201313. This review provides an excellent overview of some of the known mechanisms of action for IVIG and details how varied mechanisms may be relevant in different diseases.","journal-title":"Clin Exp Immunol"},{"key":"171_CR23","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(03)14368-1","volume":"362","author":"MC Dalakas","year":"2003","unstructured":"Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet. 2003;362:971\u201382.","journal-title":"Lancet"},{"key":"171_CR24","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1006\/clim.1999.4823","volume":"94","author":"K Amemiya","year":"2000","unstructured":"Amemiya K, Semino-Mora C, Granger RP, et al. Downregulation of TGF-beta1 mRNA and protein in the muscles of patients with inflammatory myopathies after treatment with high-dose intravenous immunoglobulin. Clin Immunol. 2000;94:99\u2013104.","journal-title":"Clin Immunol"},{"key":"171_CR25","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1093\/brain\/awh518","volume":"128","author":"R Raju","year":"2005","unstructured":"Raju R, Dalakas MC. Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIg and biological validation of clinically relevant genes. Brain. 2005;128:1887\u201396.","journal-title":"Brain"},{"key":"171_CR26","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1212\/01.WNL.0000291619.17160.b8","volume":"69","author":"SA Greenberg","year":"2007","unstructured":"Greenberg SA. Proposed immunologic models of the inflammatory myopathies and potential therapeutic implications. Neurology. 2007;69:2008\u201319.","journal-title":"Neurology"},{"key":"171_CR27","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1212\/WNL.54.1.65","volume":"54","author":"YC Choi","year":"2000","unstructured":"Choi YC, Dalakas MC. Expression of matrix metalloproteinases in the muscle of patients with inflammatory myopathies. Neurology. 2000;54:65\u201371.","journal-title":"Neurology"},{"key":"171_CR28","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.coph.2010.03.001","volume":"10","author":"MC Dalakas","year":"2010","unstructured":"\u2022 Dalakas MC. Inflammatory muscle diseases: a critical review on pathogenesis and therapies. Curr Opin Pharmacol. 2010;10:346\u201352. This reference describes some of the recent controversies in the proposed pathophysiology of the inflammatory myopathies and critically appraises the evidence behind the different theories.","journal-title":"Curr Opin Pharmacol"},{"key":"171_CR29","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/art.10053","volume":"46","author":"P Cherin","year":"2002","unstructured":"Cherin P, Pelletier S, Teixeira A, et al. Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients. Arthritis Rheum. 2002;46:467\u201374.","journal-title":"Arthritis Rheum"},{"key":"171_CR30","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/0002-9343(91)90009-M","volume":"91","author":"P Cherin","year":"1991","unstructured":"Cherin P, Herson S, Wechsler B, et al. Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients. Am J Med. 1991;91:162\u20138.","journal-title":"Am J Med"},{"key":"171_CR31","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1212\/WNL.48.3.712","volume":"48","author":"MC Dalakas","year":"1997","unstructured":"Dalakas MC, Sonies B, Dambrosia J, et al. Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study. Neurology. 1997;48:712\u20136.","journal-title":"Neurology"},{"key":"171_CR32","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1212\/WNL.43.5.876","volume":"43","author":"SA Soueidan","year":"1993","unstructured":"Soueidan SA, Dalakas MC. Treatment of inclusion-body myositis with high-dose intravenous immunoglobulin. Neurology. 1993;43:876\u20139.","journal-title":"Neurology"},{"key":"171_CR33","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1212\/WNL.44.8.1516","volume":"44","author":"AA Amato","year":"1994","unstructured":"Amato AA, Barohn RJ, Jackson CE, et al. Inclusion body myositis: treatment with intravenous immunoglobulin. Neurology. 1994;44:1516\u20138.","journal-title":"Neurology"},{"key":"171_CR34","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1212\/WNL.56.3.323","volume":"56","author":"MC Dalakas","year":"2001","unstructured":"Dalakas MC, Koffman B, Fujii M, et al. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology. 2001;56:323\u20137.","journal-title":"Neurology"},{"key":"171_CR35","first-page":"1392","volume":"330","author":"MC Dalakas","year":"1994","unstructured":"Dalakas MC. Intravenous immune globulin for dermatomyositis. N Eng J Med. 1994;330:1392\u20133.","journal-title":"N Eng J Med"},{"key":"171_CR36","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1136\/ard.61.1.37","volume":"61","author":"MG Danieli","year":"2002","unstructured":"Danieli MG, Malcangi G, Palmieri C, et al. Cyclosporin A and intravenous immunoglobulin treatment in polymyositis\/dermatomyositis. Ann Rheum Dis. 2002;61:37\u201341.","journal-title":"Ann Rheum Dis"},{"key":"171_CR37","doi-asserted-by":"crossref","first-page":"158","DOI":"10.2340\/00015555-0016","volume":"86","author":"Y Kuwano","year":"2006","unstructured":"Kuwano Y, Ihn H, Yazawa N, et al. Successful treatment of dermatomyositis with high-dose intravenous immunoglobulin. Acta Derm Venereol. 2006;86:158\u20139.","journal-title":"Acta Derm Venereol"},{"key":"171_CR38","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1136\/jnnp.65.1.107","volume":"63","author":"FL Mastaglia","year":"1998","unstructured":"Mastaglia FL, Phillips BA, Zilko PJ. Immunoglobulin therapy in inflammatory myopathies. J Neurol Neurosurg Psychiatry. 1998;63:107\u201310.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2 Pt 2","key":"171_CR39","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/01.AOG.0000253244.45837.7c","volume":"109","author":"L Williams","year":"2007","unstructured":"Williams L, Chang PY, Park E, et al. Successful treatment of dermatomyositis during pregnancy with intravenous immunoglobulin monotherapy. Obstet Gynecol. 2007;109(2 Pt 2):561\u20133.","journal-title":"Obstet Gynecol"},{"key":"171_CR40","first-page":"1092","volume":"21","author":"P Cherin","year":"1994","unstructured":"Cherin P, Piette JC, Wechsler B, et al. Intravenous gamma globulin as first line therapy in polymyositis and dermatomyositis: an open study in 11 adult patients. J Rheumatol. 1994;21:1092\u20137.","journal-title":"J Rheumatol"},{"key":"171_CR41","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/adc.72.1.25","volume":"72","author":"A Sansome","year":"1995","unstructured":"Sansome A, Dubowitz V. Intravenous immunoglobulin in juvenile dermatomyositis\u2014four year review of nine cases. Arch Dis Child. 1995;72:25\u20138.","journal-title":"Arch Dis Child"},{"key":"171_CR42","first-page":"111","volume":"38","author":"MJ Tsai","year":"1997","unstructured":"Tsai MJ, Lai CC, Lin SC, et al. Intravenous immunoglobulin therapy in juvenile dermatomyositis. Zhonghua Min Guo Xiao Erke Yi Xue Hui Za Zhi. 1997;38:111\u20135.","journal-title":"Zhonghua Min Guo Xiao Erke Yi Xue Hui Za Zhi"},{"key":"171_CR43","first-page":"2498","volume":"27","author":"SM Al-Mayouf","year":"2000","unstructured":"Al-Mayouf SM, Laxer RM, Schneider R, et al. Intravenous immunoglobulin therapy for juvenile dermatomyositis\u2014efficacy and safety. J Rheumatol. 2000;27:2498\u2013503.","journal-title":"J Rheumatol"},{"key":"171_CR44","first-page":"47","volume":"122","author":"P Cherin","year":"1995","unstructured":"Cherin P, Chosidow O, Herson S. Polymyositis and dermatomyositis. Ann Dermatol Venereol. 1995;122:47\u201354.","journal-title":"Ann Dermatol Venereol"},{"key":"171_CR45","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1001\/jama.291.19.2367","volume":"291","author":"MC Dalakas","year":"2004","unstructured":"Dalakas MC. Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA. 2004;291:2367\u201375.","journal-title":"JAMA"},{"key":"171_CR46","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1136\/ard.60.6.635","volume":"60","author":"S Geneway","year":"2001","unstructured":"Geneway S, Saudan-Kister A, Guerne P-A. Intravenous gammaglobulins in refractory polymyositis: lower dose for maintenance treatment is effective. Ann Rheum Dis. 2001;60:635\u20136.","journal-title":"Ann Rheum Dis"},{"key":"171_CR47","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s004150050005","volume":"247","author":"MC Walter","year":"2000","unstructured":"Walter MC, Lochmuller H, Toepfer M, et al. High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study. J Neurol. 2000;247:22\u20138.","journal-title":"J Neurol"},{"key":"171_CR48","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/j.1468-1331.2008.02246.x","volume":"15","author":"EFNS Task Force on the Use of Intravenous Immunoglobulin in Treatment of Neurological Diseases","year":"2008","unstructured":"\u2022\u2022 EFNS Task Force on the Use of Intravenous Immunoglobulin in Treatment of Neurological Diseases. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases. Eur J Neurol. 2008;15:893\u2013908. This paper offers evidence-based recommendations from the European Federation of Neurological Societies Task Force for the use of IVIG in treatment of neurological diseases.","journal-title":"Eur J Neurol"},{"issue":"Suppl 5","key":"171_CR49","doi-asserted-by":"crossref","first-page":"V64","DOI":"10.1007\/s00415-006-5010-2","volume":"253","author":"D Pongratz","year":"2006","unstructured":"Pongratz D. Therapeutic options in autoimmune inflammatory myopathies (dermatomyositis, polymyositis, inclusion body myositis). J Neurol. 2006;253 Suppl 5:V64\u20135.","journal-title":"J Neurol"},{"key":"171_CR50","doi-asserted-by":"crossref","unstructured":"Recher M, Sahrbacher U, Bremer J, et al. Treatment of inclusion body myositis: is low-dose intravenous immunoglobulin the solution? Rheumatol Int. 2010, Jan 1 (Epub ahead of print).","DOI":"10.1007\/s00296-009-1290-z"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-011-0171-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11926-011-0171-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-011-0171-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T10:33:46Z","timestamp":1686047626000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11926-011-0171-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4,19]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["171"],"URL":"https:\/\/doi.org\/10.1007\/s11926-011-0171-0","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,4,19]]}}}